Free Trial

CERo Therapeutics Q2 2024 Earnings Report

CERo Therapeutics logo
$1.78 -0.28 (-13.41%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CERo Therapeutics EPS Results

Actual EPS
-$33.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CERo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CERo Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

CERo Therapeutics Earnings Headlines

Cero Therapeutics reports current cash position of $8M
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
See More CERo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CERo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CERo Therapeutics and other key companies, straight to your email.

About CERo Therapeutics

CERo Therapeutics (NASDAQ:CERO), an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

View CERo Therapeutics Profile

More Earnings Resources from MarketBeat